• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
TERN

TERN

Terns Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD52.95

-0.02 (-0.03%)

Company Profile

CEO

Amy L. Burroughs

IPO Date

2021-02-05

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$52.97

Prev. Close

$52.97

Day Low

$52.95

Day High

$52.97

52W Low

$2.65

52W High

$53.19

Market Cap

$4.77B

Volume

6.33M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

7

Avg Positive

26.6%

Avg Negative

1.3%

Avg Neutral

72.0%

News Feed

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

GlobeNewsWire·6/24/2021·↑ positive

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

GlobeNewsWire·6/14/2021·↑ positive

Terns Pharmaceuticals to Host Conference Call to Discuss Top-line Results from Phase 2a LIFT Study of TERN-101 for Treatment of NASH

GlobeNewsWire·6/13/2021·↑ positive

Terns to Present at the UBS Global Healthcare Virtual Conference & Participate in the J.P. Morgan Biotech 2021 CEO Conference Call Series

GlobeNewsWire·5/19/2021·↑ positive

Terns to Present at the 19th Annual Virtual Needham HealthCare Conference

GlobeNewsWire·4/7/2021·↑ positive

Terns to Present at the Cowen 41st Annual Health Care Conference

GlobeNewsWire·2/23/2021·↑ positive

Terns Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·2/10/2021·↑ positive